FDA approves Purdue's abuse-deterrent opioid Targiniq ER for pain-management

25 July 2014

The US Food and Drug Administration has approved privately-held USA-based Purdue Pharma’s abuse-deterrent opioid analgesic Targiniq ER (oxycodone/naloxone) for the treatment of severe pain requiring long-term opioid treatment for which other therapies are inadequate.

The FDA has called prescription drug abuse a ‘public health crisis,’ which means abuse-deterrent solutions are now particularly necessary.

Targiniq ER was evaluated for safety and effectiveness in a trial of 601 people with chronic low back pain, and a safety database included more than 3,000 people treated with it.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK